Cargando…
Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
BACKGROUND: Duchenne muscular dystrophy (DMD) is a neuromuscular disease stemming from dystrophin gene mutations. Lack of dystrophin leads to progressive muscle damage and replacement of muscle with fibrotic and adipose tissue. Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357134/ https://www.ncbi.nlm.nih.gov/pubmed/37248912 http://dx.doi.org/10.3233/JND-230019 |
_version_ | 1785075428772282368 |
---|---|
author | Connolly, Anne M. Zaidman, Craig M. Brandsema, John F. Phan, Han C. Tian, Cuixia Zhang, Xueping Li, Jack Eisner, Mark D. Carrier, Ewa |
author_facet | Connolly, Anne M. Zaidman, Craig M. Brandsema, John F. Phan, Han C. Tian, Cuixia Zhang, Xueping Li, Jack Eisner, Mark D. Carrier, Ewa |
author_sort | Connolly, Anne M. |
collection | PubMed |
description | BACKGROUND: Duchenne muscular dystrophy (DMD) is a neuromuscular disease stemming from dystrophin gene mutations. Lack of dystrophin leads to progressive muscle damage and replacement of muscle with fibrotic and adipose tissue. Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF), is in Phase III development for treatment of DMD and other diseases. METHODS: MISSION (Study 079; NCT02606136) was an open-label, Phase II, single-arm trial of pamrevlumab in 21 non-ambulatory patients with DMD (aged≥12 years, receiving corticosteroids) who received 35-mg/kg intravenous infusions every 2 weeks for 2 years. The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC). Secondary endpoints included other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging. RESULTS: Fifteen patients completed the trial. Annual change from baseline (SE) in ppFVC was –4.2 (0.7) (95% CI –5.5, –2.8). Rate of decline in ppFVC in pamrevlumab-treated patients was slower than observed in historical published trials of non-ambulatory patients. MISSION participants experienced slower-than-anticipated muscle function declines compared with natural history and historical published trials of non-ambulatory patients with DMD. Pamrevlumab was well-tolerated. Treatment-emergent adverse events were mild to moderate, and none led to study discontinuation. CONCLUSIONS: nti-CTGF therapy with pamrevlumab represents a potential treatment for DMD. The lack of internal control group limits the results. |
format | Online Article Text |
id | pubmed-10357134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-103571342023-07-21 Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy Connolly, Anne M. Zaidman, Craig M. Brandsema, John F. Phan, Han C. Tian, Cuixia Zhang, Xueping Li, Jack Eisner, Mark D. Carrier, Ewa J Neuromuscul Dis Research Report BACKGROUND: Duchenne muscular dystrophy (DMD) is a neuromuscular disease stemming from dystrophin gene mutations. Lack of dystrophin leads to progressive muscle damage and replacement of muscle with fibrotic and adipose tissue. Pamrevlumab (FG-3019), a fully human monoclonal antibody that binds to connective tissue growth factor (CTGF), is in Phase III development for treatment of DMD and other diseases. METHODS: MISSION (Study 079; NCT02606136) was an open-label, Phase II, single-arm trial of pamrevlumab in 21 non-ambulatory patients with DMD (aged≥12 years, receiving corticosteroids) who received 35-mg/kg intravenous infusions every 2 weeks for 2 years. The primary endpoint was change from baseline in percent predicted forced vital capacity (ppFVC). Secondary endpoints included other pulmonary function tests, upper limb function and strength assessments, and changes in upper arm fat and fibrosis scores on magnetic resonance imaging. RESULTS: Fifteen patients completed the trial. Annual change from baseline (SE) in ppFVC was –4.2 (0.7) (95% CI –5.5, –2.8). Rate of decline in ppFVC in pamrevlumab-treated patients was slower than observed in historical published trials of non-ambulatory patients. MISSION participants experienced slower-than-anticipated muscle function declines compared with natural history and historical published trials of non-ambulatory patients with DMD. Pamrevlumab was well-tolerated. Treatment-emergent adverse events were mild to moderate, and none led to study discontinuation. CONCLUSIONS: nti-CTGF therapy with pamrevlumab represents a potential treatment for DMD. The lack of internal control group limits the results. IOS Press 2023-07-04 /pmc/articles/PMC10357134/ /pubmed/37248912 http://dx.doi.org/10.3233/JND-230019 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) License (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Research Report Connolly, Anne M. Zaidman, Craig M. Brandsema, John F. Phan, Han C. Tian, Cuixia Zhang, Xueping Li, Jack Eisner, Mark D. Carrier, Ewa Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy |
title | Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy |
title_full | Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy |
title_fullStr | Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy |
title_full_unstemmed | Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy |
title_short | Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy |
title_sort | pamrevlumab, a fully human monoclonal antibody targeting connective tissue growth factor, for non-ambulatory patients with duchenne muscular dystrophy |
topic | Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357134/ https://www.ncbi.nlm.nih.gov/pubmed/37248912 http://dx.doi.org/10.3233/JND-230019 |
work_keys_str_mv | AT connollyannem pamrevlumabafullyhumanmonoclonalantibodytargetingconnectivetissuegrowthfactorfornonambulatorypatientswithduchennemusculardystrophy AT zaidmancraigm pamrevlumabafullyhumanmonoclonalantibodytargetingconnectivetissuegrowthfactorfornonambulatorypatientswithduchennemusculardystrophy AT brandsemajohnf pamrevlumabafullyhumanmonoclonalantibodytargetingconnectivetissuegrowthfactorfornonambulatorypatientswithduchennemusculardystrophy AT phanhanc pamrevlumabafullyhumanmonoclonalantibodytargetingconnectivetissuegrowthfactorfornonambulatorypatientswithduchennemusculardystrophy AT tiancuixia pamrevlumabafullyhumanmonoclonalantibodytargetingconnectivetissuegrowthfactorfornonambulatorypatientswithduchennemusculardystrophy AT zhangxueping pamrevlumabafullyhumanmonoclonalantibodytargetingconnectivetissuegrowthfactorfornonambulatorypatientswithduchennemusculardystrophy AT lijack pamrevlumabafullyhumanmonoclonalantibodytargetingconnectivetissuegrowthfactorfornonambulatorypatientswithduchennemusculardystrophy AT eisnermarkd pamrevlumabafullyhumanmonoclonalantibodytargetingconnectivetissuegrowthfactorfornonambulatorypatientswithduchennemusculardystrophy AT carrierewa pamrevlumabafullyhumanmonoclonalantibodytargetingconnectivetissuegrowthfactorfornonambulatorypatientswithduchennemusculardystrophy |